Objective: Recent studies indicate that circulating calprotectin may serve as a biomarker in some cancers. We investigated whether this is the case for ovarian neoplasms.
Study Design: Calprotectin was analyzed with an enzyme-linked immunosorbent assay in EDTA-plasma collected prior to surgery from women with ovarian carcinomas (n = 89), borderline ovarian tumors (BOT, n = 39), and benign ovarian tumors (n = 71). Serum CA 125 was analyzed in the same study population.
Results: Median plasma calprotectin concentration was elevated in ovarian carcinoma, compared with controls, as well as compared with BOT (both P < .001). A positive correlation was found between CA 125 and calprotectin concentrations in ovarian carcinoma. Receiver operating characteristic curves demonstrated a larger area under the curve for CA 125 (0.85) as compared with calprotectin (0.70).
Conclusion: Plasma calprotectin is elevated in invasive ovarian cancer, but when used as a tumor marker, it is inferior to CA 125.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ajog.2007.10.792 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Olfactory cleft brushing: A minimally invasive tool for biomarker analysis in rhinology.
Am J Otolaryngol
December 2024
Department of Otorhinolaryngology, University of Rome Tor Vergata, Rome 00133, Italy.
Introduction: Olfactory dysfunction is a prevalent condition associated with post-viral syndromes, chronic rhinosinusitis, and neurodegenerative diseases. While olfactory cleft sampling has been investigated in neurology, its potential for assessing localized biomarkers in rhinological conditions remains underexplored. This study presents a minimally invasive nasal brushing technique specifically targeting the olfactory cleft, enabling simultaneous biomarker quantification and cytological analysis.
View Article and Find Full Text PDFRapid prediction of acute thrombosis via nanoengineered immunosensors with unsupervised clustering for multiple circulating biomarkers.
Sci Adv
December 2024
Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.
The recent SARS-CoV-2 pandemic underscores the need for rapid and accurate prediction of clinical thrombotic events. Here, we developed nanoengineered multichannel immunosensors for rapid detection of circulating biomarkers associated with thrombosis, including C-reactive protein (CRP), calprotectin, soluble platelet selectin (sP-selectin), and D-dimer. We fabricated the immunosensors using fiber laser engraving of carbon nanotubes and CO laser cutting of microfluidic channels, along with the electrochemical deposition of gold nanoparticles to conjugate with biomarker-specific aptamers and antibody.
View Article and Find Full Text PDFPlasma calprotectin as a biomarker of inflammatory activity in ulcerative colitis.
Med Clin (Barc)
November 2024
Gastroenterology Department, Centro Hospitalar e Universitário de Coimbra, 3000-075 Coimbra, Portugal; Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal.
Background: An ideal test to evaluate the inflammatory burden in ulcerative colitis is still an unmet need. Fecal calprotectin (FCP) and C-reactive protein (CRP) have significant limitations. Plasma calprotectin (PC) seems to be promising in inflammatory diseases, but its value in IBD is still to be determined.
View Article and Find Full Text PDFElevated levels of damage-associated molecular patterns HMGB1 and S100A8/A9 coupled with toll-like receptor-triggered monocyte activation are associated with inflammation in patients with myelofibrosis.
Front Immunol
October 2024
División Hematología Investigación, Instituto de Investigaciones Médicas Alfredo Lanari, Facultad de Medicina, Universidad de Buenos Aires (UBA), Buenos Aires, Argentina.
Article Synopsis
- * Two specific DAMPs, HMGB1 and S100A8/A9, were found to be elevated in MF patients and linked to higher systemic inflammation and adverse clinical outcomes, such as anemia and lower survival rates.
- * Monocytes in MF patients are hyperactivated and contribute to increased levels of S100A8/A9, while also showing a strong inflammatory response through Toll-like receptors TLR4 and TLR2, suggesting that DAMPs
Circulating Proteins Associated with Anti-IL6 Receptor Therapeutic Resistance in the Sera of Patients with Severe COVID-19.
J Proteome Res
November 2024
Département des Innovations Thérapeutiques et des Essais Précoces (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif 94800, France.
Article Synopsis
- Circulating proteomes can reveal the body's response to diseases like COVID-19 and treatments like tocilizumab, which is used to mitigate severe symptoms.
- In a study involving 28 hospitalized COVID-19 patients treated with tocilizumab, researchers collected serum samples to analyze changes in protein levels before and after treatment and assessed patient outcomes for 30 days.
- Findings indicated that specific proteins related to the complement system and Fc-epsilon receptor signaling could predict treatment success and mortality, where high complement activation linked to worse outcomes and certain signaling pathways showed lower mortality rates.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!